Palo Alto · Seed–Late Stage · 7 people tracked
Also known as SAMSARA BIOCAPITAL, LLC
Find your way into Samsara BioCapital
2,786 people in our graph share verified history with the Samsara BioCapital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Samsara BioCapital invests in the creation of transformative therapeutics for patients. The firm assembles a team of scientists, physicians, drug developers, and business leaders with hundreds of years of combined experience to back the next generation of therapeutic breakthroughs. Its ethos draws inspiration from Darwin's ideas on evolution and the branching Tree of Life, emphasizing scientific rigor and the potential for new therapeutic ideas to grow and diverge over time.
Source: firm website, verified Sep 15, 2026.
Team · 7 people
from public directories
What they invest in
from 79 of 105 portfolio companiesBiotech ×74Healthtech ×44Medical Devices ×32Deep Tech ×19Digital Health ×12AI & Machine Learning ×7Longevity ×2Cleantech ×1
HQs:United States×59Australia×1Canada×1China×1France×1
Who they back
founder profiles across 26 portfolio companiesFounding team size:solo founder×112 founders×83 founders×54+ founders×2
Where their founders studiedfrom 19 founders with education data
University of Science and Technology of China ×3Brown University ×2California State University, Long Beach ×2UC San Diego ×2University of California, Berkeley ×2
What their founders studiedfrom 18 founders with field-of-study data
Life Sciences ×8Chemistry ×5Medicine ×3Engineering ×2
Where their founders worked beforefrom 22 founders with career history
Receptos ×3Amgen ×2Avalon BioVentures ×2Broad Institute of MIT and Harvard ×2ClarVista Medical ×2
13 founders hold a PhD · 2 hold an MBA (of 21 with degree data) · backed the same founder in 2+ companies: 2 founders
Investments · 105 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 62024 · 72023 · 52022 · 52021 · 62020 · 72019 · 32018 · 22017 · 42015 · 150 dated
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Board seatSrini Akkaraju· per SEC Form D · $45.8M raise · filed Sep 2017
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesDomain AssociatesDomain PartnersPolaris Partners+1 more
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsAndera PartnersSR One Capital ManagementYsios CapitalAdams Street PartnersBoulder VenturesCatalys Pacific+1 more
Neurogene develops gene therapy treatments for rare neurological diseases.
BiotechDeep TechDigital HealthLongevityMedical DevicesNew York, US
Rachel McMinn(Founder and Chief Executive Officer)inRachel McMinn, Ph.D.(Founder and Chief Executive Officer)
BoardCory Freedland(Director)inStephen Biggar(Director)
Board seatRobert Baffi· per SEC Form D
Co-investorsEcoR1 CapitalCasdin CapitalREDMILERTW Investments L.P.William Blair
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)inPaul J. Hastings(Chief Executive Officer)in
BoardJill Carroll(Director)in
Board seatMichael Dybbs· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)RA CapitalSR One Capital ManagementAmgen VenturesLogosNorwest Venture Partners+1 more
Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.
BiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
William J. Newell(Executive Officer, Director)Jane Chung(Chief Executive Officer)inHans-Peter Gerber(Chief Scientific Officer)inDavid Pauling(Chief Administrative Officer and General Counsel)inJonathan Fawcett(VP, Head of Clinical Development)inDevendra Luhar(SVP, Technical Operations)in
Board seatMichael Bryan Dybbs· per SEC Form D
Co-investorsOwl CapitalSolasta VenturesSV Health InvestorsVida Ventures
vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.
BiotechDigital HealthMedical DevicesHigh Point, US
Rudy Howard(Executive Officer)inStephen Holcombe(Executive Officer)inLarry Altstiel(Executive Officer)Jeffrey Kindler(Executive Officer, Director)Paul Sekhri(Chairman, President, and Chief Executive Officer)inMichael Tung(Executive Vice President and Chief Financial Officer)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsJDRF T1D Fund
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
BiotechHealthtechMedical Devices
Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)Craig B. Thompson, M.D.(Founder)Brian Goff(Chief Executive Officer)in
Co-investorsARCH Venture PartnersThird Rock VenturesFlagship Ventures
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalNextech InvestOrbiMedSR One Capital ManagementvenBio PartnersWestlake Village BioPartners+1 more
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsRA CapitalSofinnova VenturesVivo CapitalNan Fung Life SciencesNovo Holdings+3 more
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.
BiotechHealthtech
Carmine Stengone(President and Chief Executive Officer)inCarmine N. Stengone(President, Chief Executive Officer and Director)inPeter T. Slover(Chief Financial Officer)inDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in
Co-investorsHadean VenturesRed Tree VentureCasdin CapitalFranklin TempletonJJDCSectoral Asset Management+1 more
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Co-investorsARCH Venture PartnersBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Omega Funds
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases such as wet AMD, diabetic eye disease, and retinal vein occlusion.
BiotechHealthtechBerkeley Heights, US
Srinivas Akkaraju(Director & Co-founder)Mike Dybbs(Director & Co-founder)inNapoleone Ferrara(Director & Co-Founder)Andrew Oxtoby(CEO & Director)inMatthew Feinsod(CMO)Liisa Bayko(CFO)
Co-investorsInvusRTW Investments L.P.
Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.
BiotechSouth San Francisco, US
Josh Lehrer(Executive Officer, Director)Katherine Stultz(Executive Officer)inPhilip Gutry(Executive Officer)Evert Schimmelpennink(Chief Executive Officer, President, Secretary, and Director)Daniel Chevallard(Chief Financial Officer)Shawn Olsson(Chief Commercial Officer)in
Co-investorsVersant Ventures
Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
BiotechDigital HealthHealthtechMedical DevicesWayne, US
Wesley H. Kaupinen(President, Chief Executive Officer and Director)Matthew E. Korenberg(Chief Financial Officer, Treasurer and Secretary)inKathleen Goin(Chief Operating Officer)inJeffrey Martini(Chief Scientific Officer)inAshley Kline(Chief Commercial Officer)in
Co-investorsBioAdvanceFrazier Life SciencesAgent Capital
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsARCH Venture PartnersGV (Google Ventures)Newpath PartnersF-Prime CapitalOUP (Osage University Partners)Arrive
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Co-investorsARCH VentureARCH Venture PartnersEcoR1 CapitalPolaris Partners
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.
BiotechHealthtechMedical DevicesAliso Viejo, US
Glenn Sussman(Co-founder)inMalik Y. Kahook(Co-founder)inPatrick Mooney(CEO)
BoardJake Merrill(Director)Geoff Pardo(Director)Bilal Khan(Director)
Co-investorsNew Enterprise Associates (NEA)RA CapitalSands Capital VenturesVensana Capital
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalTCG Crossover+2 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatMichael Dybbs· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSanofi VenturesMass General Brigham VenturesREDMILE+9 more
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardJay Lichter(Director)inTighe Reardon(Executive Officer)
Board seatMarcos Milla· per SEC Form D
Co-investorsFrazier Life SciencesLightspeed Venture PartnersAvalon BioVenturesPappas CapitalPfizer Venture InvestmentsJ.P. Morgan Asset Management+1 more
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsAscenta CapitalLongitude CapitalF-Prime Capital
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.
BiotechHealthtechMedical DevicesChanhassen, US
Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)
BoardKlaus Veitinger(Director)inImran Eba(Executive Officer)in
Co-investorsOrbiMedHealthQuest CapitalSV Health InvestorsAction Potential Venture Capital Ltd.
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inAmeet Nathwani, M.D.(Executive Officer, Director)in
Co-investorsARCH Venture PartnersEcoR1 Capital6 Dimensions CapitalGeneral CatalystInnovation EndeavorsLeaps by Bayer+5 more
.png)
Link Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors.
BiotechHealthtech
Robbie MajznerCrystal MackallJerry Cacia(Chief Operating Officer)inMark Wallet(Chief Scientific Officer)in
Co-investorsWing
Lumen develops orally delivered antibody drugs using engineered spirulina, a patented biologic platform that reduces manufacturing costs and timelines compared to conventional biologics.
BiotechDeep TechHealthtechMedical DevicesSeattle, US
Brian Finrow(Founder)in
Co-investorsWestRiver Group
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesCanaan PartnersConnecticut InnovationsPfizer Venture Investments+4 more
PsiThera is a biotechnology company using computational and physics-based methods—including quantum mechanics, molecular dynamics, machine learning, and simulation—for mechanism-driven drug design and discovery.
AI & Machine LearningBiotechDeep Tech
Co-investorsLightstone Ventures
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsThe Column GroupBain Capital Life SciencesCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more
Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.
BiotechDeep TechHealthtechMedical Devices
BoardSrini Akkaraju(Director, Founder)inPaul Kang(Director, Founder)
Co-investorsVersant VenturesGilead Sciences
Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.
BiotechDeep TechMedical Devices
George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in
Co-investorsPfizer VenturesRA CapitalSV Health InvestorsPfizer Venture InvestmentsM Ventures
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
C. Alexander Kamb(Director)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardDavid Goeddel(Director)in
Board seatSrini Akkaraju· per SEC Form D
Co-investorsNextech InvestVida VenturesThe Column Group
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Founder and Board Director)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSusan Tousi(Chief Executive Officer)in
Board seatMichael Dybbs· per SEC Form D
Co-investorsAV8 VenturesForesite CapitalIllumina VenturesInitiate Venture PartnersMenlo VenturesOpen Field Capital+5 more
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)in
BoardPETER THOMPSON(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Board seatSrinivas AkkarajuMichael Dybbs· per SEC Form D · $50M raise · filed Sep 2018
Co-investorsAccess BiotechnologyMission BiocapitalSofinnova VenturesMission Bay CapitalNew Leaf Venture PartnersOrbiMed+1 more
A2 Biotherapeutics develops cell therapy technology using the Tmod platform, which applies quantitative drug discovery methods to treat cancer patients.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Jim Robinson(CEO)in
Co-investorsThe Column Group
Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
BiotechHealthtechMedical DevicesParis, FR
Marc de Garidel(CEO)in
Co-investorsAndera PartnersClaret Capital PartnersMedicxiSofinnova PartnersTruffle CapitalMorgan Stanley
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsDecheng CapitalvenBio PartnersAccess IndustriesKleiner PerkinsWestlake Village BioPartners
Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope).
BiotechDeep TechHealthtechFremont, US
Yuling Luo(Co-founder, CEO and Chair)inSteve Chen(Co-founder, COO and Director)inYiyuan Yin(Co-founder, VP of Technology)inTod White(President)inJustin McAnear(CFO)inXiao-Jun Ma(CTO)
Co-investorsIllumina VenturesQiming Venture Partners
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersRoche Venture Fund
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude Capital+9 more
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSixty Degree CapitalSolasta VenturesSR One Capital Management+5 more
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Co-investorsAlpha Wave GlobalBioBritvenBio PartnersJanus Henderson InvestorsREDMILEvenBio Global Strategic+1 more
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersPfizer Venture InvestmentsNewpath Partners
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalOrbiMedTCG CrossoverThird Rock VenturesvenBio PartnersVida Ventures
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny VentureThird Rock Ventures
Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.
BiotechHealthtechMedical DevicesJersey City, US
Clarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)Susan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSofinnova VenturesCatalio Capital ManagementNovo Holdings
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMarie De Vulder(Chief Legal Officer Co-founder)inGuy Peeters(Chief Financial Officer Co-founder)inJohn-Paul Gallivan(Head of Development Co-founder)inFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in
Co-investorsLongwood FundSofinnova VenturesBAM ElevateFinchley Healthcare VenturesForbionLuma Group+1 more
Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.
CleantechClimate TechDeep TechNew Materials
Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in
Co-investorsPacific Channel3E Bioventures CapitalARCH Venture PartnersEcoR1 CapitalGeneral CatalystLeaps by Bayer+2 more
ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.
BiotechDeep TechHealthtechWaltham, US
David Hallal(CEO)inMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in
Co-investorsEcoR1 CapitalMPM BioImpactSoftBank Vision Fund
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)inAlexandra Cantley(Director)inSeiji Miyahara(Director)in
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundTaiho Ventures, LLC+4 more
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian
Co-investorsNewpath PartnersCRV (Charles River Ventures)Nextech InvestRaptor GroupBiotechnology Value FundCasdin Capital+1 more
Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries.
BiotechDeveloper Tools
Co-investorsCivilization Ventures Management, LlcCota CapitalIllumina Ventures
Genalyte develops Merlin, a real-time diagnostic system that performs laboratory testing directly in clinical settings and integrates results with electronic health records.
Digital HealthHardwareHealthtechMedical DevicesSan Diego, US
Cary Gunn(Co-founder and Chief Technical Officer)in
Co-investorsBioBritBoutique Venture PartnersClaremont Creek VenturesFusionX VenturesIPD CapitalSeed Healthcare+3 more
XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding.
BiotechFintech
Co-investorsCatalys PacificFrazier Life SciencesLightspeed Venture PartnersRA CapitalFrazier Healthcare Partners
Intercept Pharmaceuticals develops and commercializes treatments for rare and serious liver and other diseases, with a focus on conditions such as primary biliary cholangitis.
BiotechHealthtechMedical Devices
Co-investorsAisling CapitalBioBritRidgeback Capital
Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.
BiotechMedical Devices
Co-investorsEuropean Investment BankAndera PartnersClaret Capital PartnersNew Enterprise Associates (NEA)Sofinnova PartnersBiotechnology Value Fund+1 more
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsAvoro Capital AdvisorsEIR VenturesKurma PartnersRA CapitalSunstone CapitalVivo Capital+2 more
IonPath develops MIBIscope, a spatial proteomics platform that uses multiplexed ion beam imaging to simultaneously measure dozens of protein targets in preserved tissue samples for translational research and discovery.
BiotechDeep TechMedical Devices
Co-investorsHemisphere Ventures LLCNorwich VenturesVertical Venture Partners
Janux Therapeutics develops precision-engineered bispecific immunotherapies, including tumor-activated T cell engagers (TRACTr), designed to modulate T cells to treat cancer and autoimmune diseases.
BiotechMedical DevicesLa Jolla, US
David Campbell, Ph.D.(Executive Officer, Director)inTighe Reardon(Executive Officer)
BoardJay Lichter, Ph.D.(Director)Jake Simson, Ph.D.(Director)Peter Thompson, M.D.(Director)inStefan Heller(Director)
Co-investorsAvalon BioVenturesOrbiMed
HealthtechSkokie, US
Sara Cotter(Executive Officer, Director, Promoter)Michael Dybbs(Director)Sara Brownstein(Director)Terrence Kearney(Director)Daniel Welch(Director)Steven Ryder(Director)
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)in
Co-investors5AM VenturesOrbiMedvenBio PartnersVivo CapitalRTW Investments L.P.venBio Global Strategic+1 more
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsEcoR1 CapitalLAVLilly Asia VenturesRA CapitalThe Innovation SpaceLogos
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsThe Column GroupSanofi Ventures
Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.
BiotechHealthtechResearch Triangle Park, US
BT Slingsby(Co-Founder & Executive Chairman)in
Co-investorsAbingworthCatalys PacificOrbiMedKB Investment
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCharles McDermott(President & CEO, Director)
BoardTodd J Harris(Director)in
Co-investorsBioBritBioRock VenturesBioqube VenturesOberland CapitalPolaris Partners
BiotechFremont, US
Avanish Vellanki(Executive Officer)in
Co-investorsBiotechnology Value FundJanus Henderson Investors
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Co-investorsScion Life SciencesSofinnova VenturesTCG CrossovervenBio PartnersVersant VenturesVivo Capital+1 more
Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension.
BiotechDigital HealthHealthtechMedical Devices
John Kollins(Chief Executive Officer)in
Co-investorsCottonwood Technology FundZentynel Frontier Investments
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in
Co-investorsCatalio Capital Management, LPRA CapitalVertex Ventures HCThird Rock Ventures
Simcha is a biotechnology company developing new cancer medicines based on immune biology research.
BiotechHealthtechNew Haven, US
Aaron Ring(Executive Officer, Director)inBeatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)
Co-investorsConnecticut InnovationsPfizer Venture InvestmentsSR One Capital ManagementAxial VCBiotechnology Value FundRock Springs Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Chinook Therapeutics U.SFl2021-001Lumen BioscienceSyros Pharmaceuticals, Inc.Adverum BiotechnologiesAlentarAlpheusAutobahn Labs, LLCBE BiopharmaBionic Sight, Inc.Chinook TherapeuticsCodex Health, Inc.Decibel TherapeuticsDICE TherapeuticsEnara Bio, Ltd.Excellergy TherapeuticsEyebiotech LimitedForma TherapeuticsGraphite Bio, Inc.IntegerBio, Inc.IVERIC BioLink Cell TherapiesMaro BioMemento MedicinesMiroBioNkarta TherapeuticsOnKure, Inc.OttimoPalladio BiosciencesRaniRespira TherapeuticsShenandoahSideraTentarix Biotherapeutics, LPVelicept TherapeuticsVignette Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 26
19 IPOs · 7 acquisitions · showing 25aTYR PHARMANASDAQ: ATYRMineralys TherapeuticsNASDAQ: MLYSNeurogeneNASDAQ: NGNENkarta, Inc.NASDAQ: NKTXSutrobioNASDAQ: STROVtvtherapeuticsNASDAQ: VTVTAgios PharmaceuticalsNASDAQ: AGIOAlumisNASDAQ: ALMSBolt BiotherapeuticsNASDAQ: BOLTContineum TherapeuticsNASDAQ: CTNMGossamer BioNASDAQ: GOSSKalaris Therapeutics, Inc.NASDAQ: KLRSLENZ Therapeutics, Inc.NASDAQ: LENZPalvellatxNASDAQ: PVLAPrime MedicineNASDAQ: PRMEScholar Rock Holding Corp, Inc.NASDAQ: SRRKSpyglass PharmaNASDAQ: SGPUpstream BioNASDAQ: UPBAcelyrinacq. by AlumisDecibel Therapeuticsacq. by RegeneronExcellergy Therapeuticsacq. by NovartisEyebiotech Limitedacq. by MerckForma Therapeuticsacq. by Novo NordiskHilleVaxacq. by XOMA RoyaltyIntercept Pharmaceuticalsacq. by Alfasigma
Portfolio news
latest coverage across their companiesNeurogene · stocktitan.net · Sep 8, 2026
LENZ Therapeutics, Inc. · seekingalpha.com · Sep 4, 2026
Prime Medicine · biospace.com · Sep 3, 2026
Lumen · finance.yahoo.com · Aug 26, 2026
Inventiva · themarketsdaily.com · Aug 26, 2026
Contineum Therapeutics · stocktitan.net · Aug 25, 2026
Abcuro · clinicaltrialsarena.com · Aug 19, 2026
Mineralys Therapeutics · mychesco.com · Aug 18, 2026
IPO stake values · per SEC filings · 6
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| LENZ Therapeutics, Inc. | 12.4% | $17.00 | Jun 2021 | $117.8M |
| Mineralys Therapeutics | 9.2% | $16.00 | Feb 2023 | $57.3M |
| Upstream Bio | 4.0% | $17.00 | Oct 2024 | $35.1M |
| Alumis | 3.3% | $16.00 | Jun 2024 | $27.3M |
| Spyglass Pharma | 4.7% | $16.00 | Feb 2026 | $23.8M |
| Sutrobio | 4.1% | $15.00 | Sep 2018 | $13.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Samsara BioCapital made?
- Samsara BioCapital has 105 tracked investments, 26 of which have exited, including 11 dated in the last 24 months.
- What stage does Samsara BioCapital invest at?
- Samsara BioCapital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Samsara BioCapital focus on?
- Samsara BioCapital focuses on Biotech, Healthtech, Medical Devices.
- Where is Samsara BioCapital located?
- Samsara BioCapital is headquartered in Palo Alto, US.
- Who does Samsara BioCapital co-invest with?
- Samsara BioCapital most often shares deals with RA Capital, New Enterprise Associates (NEA), OrbiMed, among 101 tracked co-investors.
- What size deals does Samsara BioCapital back?
- Across 6 deals with disclosed amounts, Samsara BioCapital has joined rounds of $60M – $115M (median $75.9M).
Co-investors · 18
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
▶6 more co-investors
Advent Life SciencesLightstone VenturesEQT Life SciencesFlagship PioneeringGenoa VenturesAmplitude Venture Capital
Firms observed investing alongside Samsara BioCapital, from public investor directories. Shared companies are the overlap with Samsara BioCapital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.